Navigation Links
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
Date:7/18/2012

HAYWARD, Calif., July 18, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any.  The Company intends to use the net proceeds from the offering for general corporate purposes.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 

Piper Jaffray & Co. and Leerink Swann LLC are acting as joint book-running managers in the offering. 

The securities described above are being offered by the Company pursuant to a shelf registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC").  A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov.  Copies of the preliminary prospectus supplement relating to these securities, when available, may be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at prospectus@pjc.com, or from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by telephone at 800-808-7525 or by email at Syndicate@Leerink.com. 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in whi
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
7. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
8. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
11. Icahn Issues Statement Regarding Amylin Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
(Date:4/16/2014)... marvel of the embryo. It begins as a glob of ... to become the cells of our lungs, muscles, nerves and ... in a feat of reverse tissue engineering, Stanford University researchers ... embryonic cells to proliferate and transform into all of the ...
(Date:4/16/2014)... Therapeutics, Inc. (NASDAQ: CLDX) announced today that final data ... tumors, including long-term patient follow-up, have been published in ... The data demonstrate robust antibody and T cell responses ... advanced cancers and suggest that CDX-1401 may predispose patients ...
(Date:4/16/2014)... DOWNERS GROVE, Ill. April 16, 2014 According ... surveillance colonoscopy in average-risk patients with one to two ... 90 percent of cases. This may be an appropriate ... endoscopic database study to quantify adherence to guidelines for ...
(Date:4/15/2014)... Cases of diabetes and pre-diabetes in the United States have ... Hopkins Bloomberg School of Public Health, with obesity apparently to ... burden of the disease has not hit all groups equally, ... elderly. , According to new research reported in the April ...
(Date:4/15/2014)... solved a decades-old medical mystery and in the process have ... which kill about 1.5 million people a year. The researchers say ... drug that has been in use for more than 50 years ... as it is to the microbes it attacks. , A ...
Breaking Medicine News(10 mins):Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3
... , WEDNESDAY, Jan. 4 (HealthDay News) -- Remember those ... but you took the plunge and whizzed downward. Next, ... and hanging by your knees at the pinnacle. ... sliding boards, safer plastic climbers and fence-protected platforms are ...
... CareFirst BlueCross BlueShield (CareFirst) today announced that it has ... make available the ACP,s Medical Home Builder 2.0 ... (PCMH) practices. The ACP developed MHB 2.0 as ... care, organization, and workflow. CareFirst is making the ...
... By Serena Gordon HealthDay Reporter , TUESDAY, ... in the United States are far more likely to be ... 16 other countries, a new study indicates. Researchers suspect ... days in the United States compared with at least six ...
... -- The current issue of Medical Acupuncture , ... explores how the U.S. military is incorporating medical acupuncture ... serving in the war zones and the efforts underway ... available online at http://www.liebertpub.com/acu . "The use ...
... pharmaceutical industry continues to globalize, the challenges of securing ... as well as the consequences of lapses in security ... encourage comprehensive public standards across the pharmaceutical industry, the ... recommended best practices that will help ensure that medicines ...
... of two substances in licorice used extensively in Chinese ... tooth decay and gum disease, the leading causes of tooth ... Journal of Natural Products , they say that these ... decay and gum disease. Stefan Gafner and colleagues ...
Cached Medicine News:Health News:'Safety-First' Playgrounds Linked to Bored, Inactive Kids: Study 2Health News:'Safety-First' Playgrounds Linked to Bored, Inactive Kids: Study 3Health News:CareFirst BCBS and ACP offer new tool to advance development of patient-centered medical homes 2Health News:CareFirst BCBS and ACP offer new tool to advance development of patient-centered medical homes 3Health News:U.S. Heart Attack Patients Readmitted Most Often: Study 2Health News:U.S. Heart Attack Patients Readmitted Most Often: Study 3Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 2Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 3Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: